Monitor for enrollment updates or initial data from the Phase 1/2 TNBC trial, which is the primary near-term catalyst. The AMD data is exploratory and does not change the clinical or regulatory timeline.
Price Chart
Executive Summary
Telomir Pharmaceuticals published peer-reviewed preclinical data showing Telomir-Zn improved visual function and reduced retinal degeneration in an AMD model, with mechanistic evidence linking intracellular metal modulation to epigenetic regulation. The company's clinical focus remains on oncology (Phase 1/2 TNBC trial), and this non-clinical data does not change the near-term regulatory or financial outlook.
Key Facts
- Telomir-Zn significantly improved visual function, restored retinal structure, and reduced mitochondrial oxidative stress in a zebrafish AMD model.
- Telomir-Zn dose-dependently increased relative telomeric DNA content and restored altered DNA methylation patterns.
- Telomir-Zn inhibited iron-dependent Jumonji C histone demethylases (KDMs), with strongest activity against KDM5B at IC50 of 63 nM.
- Company's clinical priority remains oncology; Phase 1/2 trial in advanced/metastatic triple-negative breast cancer is FDA-cleared.
- Preclinical findings are non-clinical and do not alter the company's current development or regulatory milestones.
Financial Impact
No financial figures disclosed; preclinical publication with no immediate revenue or cost impact.
Risk Factors
- Preclinical results may not translate to human efficacy in AMD or other indications.
- Company remains pre-revenue with no approved products; clinical-stage risk is high.
- No financing or partnership announced to support expanded development beyond oncology.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3363965 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $1.20 | awaiting T+20 | — | $0.9990 (−16.75%) |
Sep 17, 2026 5w ago | 8-K | $1.12 $1.05 | ▼ −6.25% | ▼ −7.46% | $0.9990 (−10.80%) |
Sep 17, 2026 5w ago | Press Release | $1.12 $1.05 | ▼ −6.25% | ▼ −7.71% | $0.9990 (−10.80%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $1.10 | ▼ −5.98% | ▼ −8.25% | $0.9990 (−14.62%) |
Aug 19, 2026 9w ago | DEFA14A | $1.17 $1.12 | ▼ −4.27% | ▼ −2.32% | $0.9990 (−14.62%) |
Aug 10, 2026 11w ago | 8-K | $1.17 $1.19 | ▲ +1.71% | ▲ +2.62% | $0.9990 (−14.62%) |
Jun 15, 2026 19w ago | 8-K | $1.29 $1.24 | ▼ −3.88% | ▼ −3.13% | $0.9990 (−22.56%) |
Jun 8, 2026 20w ago | 8-K | $1.21 $1.24 | ▲ +2.48% | ▲ +1.03% | $0.9990 (−17.44%) |
Apr 24, 2026 26w ago | 8-K | $1.40 $1.30 | ▼ −7.14% | ▼ −11.17% | $0.9990 (−28.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers